Net Loss per Share

3 Months Ended

Mar. 31, 2018

Net Loss per Share

Net Loss per Share

11.   Net Loss per Share

Basic and diluted net loss per share attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd. was calculated as follows:

	Three Months Ended March 31,
	2018			2017
Numerator:
Net loss	$	(85,462	)	$	(18,753	)
Accretion of beneficial conversion feature on Series A preferred shares	—			(4,000		)
Net loss attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd.	$	(85,462	)	$	(22,753	)
Denominator:
Weighted average common shares outstanding—basic and diluted	36,793,090			13,088,861
Net loss per share attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd.—basic and diluted	$	(2.32	)	$	(1.74	)

The Company’s potential dilutive securities, which include stock options and warrants to purchase common shares, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common shareholders of the Company is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:

	Three Months Ended March 31,
	2018	2017
Options to purchase common shares	5,979,093	4,345,344
Warrants to purchase common shares	546,751	815,000
	6,525,844	5,160,344